They found that JAK2 inhibition prevented tumor PD-L1 expression and that the combination enhanced the CTX NK-mediated killing via ADCC against PD-L1+ HNSCC cells. This evidence concerns the gene JAK2 and head and neck squamous cell carcinoma.